Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant antibody construct against human CD30 and CD16A

EU orphan designation number: EU/3/09/673   
Active ingredient: Recombinant antibody construct against human CD30 and CD16A
Indication: Treatment of Hodgkin lymphoma
Sponsor: Affimed Therapeutics AG
Im Neuenheimer Feld 582, D-69120 Heidelberg, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/10/2009 Centralised Orphan - Designation EMEA/OD/046/09 (2009)7922 of 09/10/2009